Recursion Pharmaceuticals (RXRX) Expected to Announce Earnings on Monday

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.44) per share and revenue of $18.12 million for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company's revenue was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.42) earnings per share. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:RXRX traded down $0.05 during midday trading on Tuesday, reaching $5.80. 4,355,799 shares of the company's stock were exchanged, compared to its average volume of 12,257,760. The firm's 50 day simple moving average is $6.11 and its two-hundred day simple moving average is $6.78. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -3.79 and a beta of 1.00.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, KeyCorp reduced their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $8.20.

Hedge Funds Weigh In On Recursion Pharmaceuticals

An institutional investor recently raised its position in Recursion Pharmaceuticals stock. Brighton Jones LLC increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 49.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,261 shares of the company's stock after buying an additional 6,699 shares during the period. Brighton Jones LLC's holdings in Recursion Pharmaceuticals were worth $137,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.